OXFORD, England, July 31, 2023 /PRNewswire/ -- Applying AI to a single apical four chamber (A4C) view echocardiogram provides accurate information to detect heart failure with preserved ejection fraction (HFpEF), according to research published today in JACC Advances.
The study, presented at the American Society of Echocardiography Annual Scientific Session, demonstrates the platform could improve the diagnosis, management, and outcomes of a condition that currently often goes undetected, or requires additional invasive procedures to confirm.
Ultromics' EchoGo® Heart Failure accurately detected HFpEF and provided fewer non-diagnostic outputs than current clinical scores, using just the routinely acquired A4C view from a transthoracic echocardiographic (TTE). The novel technology, which was recently granted clearance and Breakthrough Device designation by the FDA, identifies radiomic signatures of disease that are not evident to the human eye.
Ad Statistics
Times Displayed: 46680
Times Visited: 1311 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Senior study author, Patricia A. Pellikka, M.D, Vice Chair in the Department of Cardiovascular Medicine at Mayo Clinic, said: "HFpEF can be difficult to detect, but left undetected and untreated, can result in hospitalization and mortality. As the first AI platform cleared to detect the condition, EchoGo® Heart Failure can fill a significant unmet need."
"With more than 32 million people living with HFpEF, and the incidence increasing, clinicians will benefit from having another means to recognize this disease."
Based on the AI findings, patients could potentially be started on medications to treat their condition earlier than if they had to wait for an invasive diagnostic assessment of the disease.
The AI model was trained and developed on 6,756 patients who underwent a comprehensive TTE at Mayo Clinic in Rochester, Minnesota, between January 2009 to December 2020. It was then independently tested in geographically distinct areas within Mayo Clinic enterprise System sites across the United States, on a dataset that included 1,284 patients.
EchoGo® Heart Failure demonstrated high sensitivity and specificity, detecting 87.8% of patients who had HFpEF, and 81.9% of patients that did not.1 These results exceed what is usually observed in routine clinical practice.
It was also able to assign a correct diagnosis to 74% of patients who had returned non-diagnostic results on the commonly used HFA-PEFF and H2FPEF clinical scores.1 This improvement could translate to more patients receiving accurate and timely diagnoses and management.
